In another example, in combination with systemic administration of anti-PD-1 antibody pembrolizumab, intratumoral injection of T-VEC altered the tumor environment and increased cytotoxic CD8+ T cell infiltration in melanoma patients. This evidence concerns the gene PDCD1 and neoplasm.